After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Peter Hansen. A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also be effective in tackling Alzheimer's disease.The study ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

Novo Nordisk’s once-weekly semaglutide has outperformed another weekly therapy, dulaglutide, in controlling blood glucose and helping patients with type 2 diabetes (T2D) lose weight.

Novo Nordisk A/S NVO announced positive top-line results from its phase IIIb PIONEER PLUS study. The study evaluates the safety and efficacy of its once-daily oral semaglutide 25 mg and 50 mg ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

According to analysis by Novo Nordisk, more than half of the Chinese suppliers that shipped "semaglutide" into the US for compounding or further manufacturing in 2024 – and so far in 2025 ...